Archive | Melanoma News

Lessons From Clinical Trial Setbacks Lead to Next Phase of Oncologic Advances

It was certainly inevitable. In the wake of the enthusiasm around cancer immunotherapy trial results—with several positive trials presented annually at each American Society of Clinical Oncology (ASCO) meeting in more and more diseases over several years—setbacks have served as a grim reminder that our work isn’t finished.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

BMS’ Opdivo plus Yervoy misses the mark in high-risk melanoma

Bristol Myers Squibb has revealed some underwhelming results for its immunotherapy combination treatment Opdivo plus Yervoy in resected high-risk melanoma patients.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

CheckMate-915 Trial Does Not Meet Co-Primary End Point of RFS for Melanoma

Updated results from the randomized, phase 3 CheckMate-915 trial found that nivolumab (Opdivo) plus ipilimumab (Yervoy) did not result in a statistically significant improvement in recurrence-free survival (RFS) in the intention-to-treat population of participants, according to Bristol Myers Squibb, the developer of the agents.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Melanoma Not Associated With Menopausal Hormone Therapy, Reproductive Factors

Melanoma is not associated with either reproductive factors or menopausal hormone therapy use, according to study data published in the British Journal of Dermatology.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest